Correction for “Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients” Rev Urol. 2018;20(2):63-68 doi: 10.3909/riu0798

Erratum Correction for “Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients” Rev Urol. 2018;20(2):63-68 doi: 10.3909/riu0798 [Rev Urol. 2019;21(2/3):144] © 2019 MedReviews®, LLC D ue to a typesetting error, there was an incorrect value listed in the y-axis, column 7, of Figure 3 on page 67 of Pieczonka CM et al. Effectiveness of subcutaneously administered leuprolide acetate to achieve low nadir testosterone in prostate cancer patients. Rev Urol. 2018;20(2):63-68. The corrected figure appears below and a corrected PDF of the article may be found online at http:// medreviews.com/journal/reviews-in-urology/ vol/20/no/2/effectiveness-subcutaneously-administered-leuprolide-acetate-achieve-low-nadir-testosterone-in-prostate-cancer-patients. We regret the inconvenience this error may have caused. 99% T #20 ng/dL 1% T >20 ng/dL 97% T #10 ng/dL 100 Percent 80 91% T #5 ng/dL 80 60 40 20 11 5 0 #3 .3-5 .5-8 1 1 1 0 1 .8-10 .10-15 .15-20 .20-50 .50 Nadir Testosterone (ng/dL) Figure 3. Proportion of patients by nadir testosterone level achieved over study duration (n 5 437). 144 • Vol. 21 No. 2/3 • 2019 • Reviews in Urology